Long-term pharmacokinetics of doxorubicin HCI stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP)

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 3, 2001, Pages 179-184

  Linkesch, W ^a   Weger, M ^a   Eder, I ^b   Auner, H W ^a   Pernegg, C ^b   Kraule, C ^b   Czejka, M J ^b  

^a UNIVERSITY HOSPITAL GRAZ   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Caelyx stealth liposomes; Doxorubicin; Pharmacokinetics; Polychemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DEOXYCORTICOSTERONE ACETATE; DOXORUBICIN; NAVELBINE; PREDNISONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; MALE; NEUTROPENIA; PLASMA CLEARANCE;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG CARRIERS; DRUG INTERACTIONS; ETOPOSIDE; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; KARNOFSKY PERFORMANCE STATUS; LIPOSOMES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS;

EID: 0034779854     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190394     Document Type: Article

References (22)

1. Impact of scheduling of toxicity and clinical efficacy of doxorubicin: What do we know in the mid-nineties?
2. Liposomes containing synthetic lipid derivatives of poly(erhylene glycol) show prolonged circulation half lives in-vivo
3. Microscopic localisation of sterically stabilised liposomes in colon carcinoma bearing mice
4. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIC tat gene
5. Pharmacokinetics and tumour localisation of DOX-SL (Stealth liposomal doxorubicin) by comparison with Adriamycin in patients with AIDS and Kaposi's sarcoma
6. Relationship of dose intensity to the induction of palmar-plantar erythro-dysesthia by pegylared liposomal doxorubicin in dogs
7. A predictive model for aggressive Non-Hodgkin's Lymphoma
8. High performance liquid chromato-graphic determination of adriblastin in human plasma, urine, saliva and liver punctuate by column switching for drug monitoring studies
9. Serum and tissue concentrations of doxorubicin in patients receiving i.v. mono- and polychemotherapy of encapsulated doxorubicin (stealth liposomes, Caelyx)
10. Repeated high dose cyclophosphamide administration in bone marrow transplantation; exposure to active metabolites
11. Adriamycin pharmacokinetics in children
12. Interactions between cyclophosphamide and adriamycin in rats
13. Interaction between cyclophosphamide and doxorubicin. Meta-bolism in rat, effect of cyclophosphamide aldoketoreductase system
14. Vinorelbine high affinity binding to human platelets and lymphocytes: Distribution in human blood
15. Pharmacokinetic and preliminary metabolic fare of navelbine in humans as determined by high performance liquid chromatography
16. Liposomes: Opportunities in drug delivery
17. Pharmacokinetics of Caelyx®, Doxil® (Stealth® liposomal doxorubicin) in patients with breast or prostate cancer
18. Prolonged circulation-time and enhanced accumulation in malignant exsudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
19. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumour localization and safety in patients with AIDS related Kaposi sarcoma